New Analysis from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at IPNA

New Analysis from ILLUMINATE-C Phase 3 Study of Lumasiran Presented at IPNA

Results from a post-hoc analysis of patients on hemodialysis in the ongoing ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the International Pediatric Nephrology Association (IPNA) Congress (Sept. 7-11, 2022).

Michael, et al. “Relationship of Baseline Weight and Response to Lumasiran in Patients With Primary Hyperoxaluria Type 1 on Hemodialysis”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.